查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445546

移植物抗宿主疾病（GvHD）市场评估：按疾病类型、药物类别、给药途径、最终用户和地区划分的机会和预测（2017-2031）

Graft versus Host Disease Assessment, By Disease Type, By Drug Class, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 237 Pages | 商品交期: 3-5个工作天内

价格

全球移植物抗宿主疾病 (GvHD) 市场规模将从 2023 年的 29.9 亿美元增至 2031 年的 61 亿美元，2024-2031 年预测期间复合年增长率为 9.51%。预计将增长至9000万美元。

由于器官移植和干细胞移植等移植需求的增加、技术进步、政府举措以及人工智慧的整合等因素，GvHD 市场正在不断增长。 移植需求的不断增加正在推动 GvHD 的流行，并加速对治疗方案的需求。 患者正在寻找更可靠、无麻烦和一流的方法来管理移植后症状。 此外，政府也大力投资研发，将最好的技术推向市场。 许多新进展正在帮助接受移植手术的患者恢復得更快、更好。

GvHD 盛行率增加

由于干细胞移植的增加，GvHD 市场正在显着扩大。 干细胞移植是治疗多种免疫学和血液学问题的一种强大的新方法。 然而，随着移植手术的增多，GvHD的盛行率也在增加。 干细胞移植已成为多种疾病的常见治疗方法。 有使用病人干细胞的自体移植和使用捐赠者干细胞的同种异体移植。 再生障碍性贫血和严重复合型免疫缺陷（SCID）等非恶性疾病以及白血病、淋巴瘤和骨髓瘤等血液恶性肿瘤的治疗都受益于这些疗法。 随着越来越多人接受干细胞移植，发生 GvHD 的风险也会增加。 除了传统用途之外，医生和研究人员正在研究支持实体器官移植、自体免疫疾病移植和再生医学的应用。 随着移植手术的多样化，面临 GvHD 风险的患者数量不断增加，对有效 GvHD 治疗的需求进一步增加。

政府措施

对 GvHD 治疗的生产和批准的持续监管支持是市场成长的关键驱动力之一。 GvHD 研究、临床研究和有前景药物的商业化得到了政府和私营部门的大力资助。 政府已采取主动与该领域的研究中心、医疗专业人员和研究机构合作。

技术进步

GvHD 治疗技术正在以惊人的速度发展，这主要归功于医疗技术的进步。 由于医疗技术的进步，诊断GvHD的能力已大大提高。 利用基因组定序、生物标记识别和高解析度成像，医疗保健专业人员可以高精度检测 GvHD。 医疗技术的进步使得专门针对 GvHD 患者的需求而设计的针对性治疗成为可能。 GvHD 有前景的治疗方法包括免疫调节药物、生物製剂和单株抗体。 基于这些免疫学特征的精确定製药物提供了危害较小、更好的疾病控制方法。

本报告调查了全球移植物抗宿主疾病(GvHD) 市场，并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、产业结构和市场成长。它总结了以下分析：影响因素、案例研究、竞争格局、主要公司概况。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球移植物抗宿主疾病 (GvHD) 市场展望

  • 市场规模/预测
  • 依疾病类型
    • 急性移植物抗宿主疾病
    • 慢性移植物抗宿主疾病
  • 依药物类别
    • 单株抗体
    • 免疫抑制剂
    • 类固醇
    • TNF抑制剂
    • 其他
  • 依给药途径
    • 口头
    • 静脉注射
    • 其他
  • 按最终用户
    • 医院药房
    • 零售药局
    • 网路药局
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第 5 章按地区划分的全球移植物抗宿主疾病 (GvHD) 市场展望

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 依疾病类型
  • 依药物类别
  • 依给药途径
  • 按最终用户
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 生长抑制因素（问题、限制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Merck & Co., Inc
  • Novartis AG
  • Astellas Pharma Inc.
  • Astra Zeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International Gmbh
  • Abott Inc.
  • Bristol Myers Squibb
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Eli Lilly and Company

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX11095

Global graft versus host disease market is projected to witness a CAGR of 9.51% during the forecast period 2024-2031, growing from USD 2.99 billion in 2023 to USD 6.19 billion in 2031. The graft versus host disease (GvHD) market is experiencing growth due to factors such as rising demand for transplants, such as organ transplants or stem cell transplants, advancements in technology, government initiatives, and the integration of AI. Increasing demand for transplantations has boosted the prevalence of GvHD, which, in turn, has accelerated the demand for treatment options. Patients are looking for a more reliable, hassle-free, and best possible approach to deal with the symptoms that come after the transplantations. Furthermore, the government is also spending significant amounts on research and development to bring out the best possible techniques in the market. Many new advancements are helping faster and better recovery of patients after undergoing transplantation procedures.

Results from a phase 2 study (NCT02867384) presented during the 2023 ASH Annual Meeting showed that using obinutuzumab (Gazyva) to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic GvHD undergoing well-matched hematopoietic stem cell transplant.

Rising Prevalence of GvHD

The market for GvHD is expanding significantly due to the rising use of stem cell transplants. A potent new technique for treating several immunological and hematological problems is stem cell transplantation. However, the prevalence of GvHD has increased in tandem with the growth in transplant procedures. Stem cell transplants have become a common therapy option for a variety of illnesses. They can be performed autologously, using the patient's stem cells, or allogeneically, using donor stem cells. Treatments for non-malignant conditions, including aplastic anemia and severe combined immunodeficiency (SCID), as well as hematological malignancies like leukemia, lymphoma, and myeloma, are both benefiting from this rising use. There is a growing risk of developing GvHD as more individuals receive stem cell transplantation. Beyond the conventional applications, physicians and researchers are investigating solid organ transplant support, autoimmune disease transplantation, and regenerative medicine applications. The demand for efficient GvHD treatments is being further driven by the expansion of the patient pool at risk of developing GvHD due to the diversity of transplant procedures.

In the United States, 42% of patients had developed chronic (cGvHD) within three years following allogenic HCT; 66% of those impacted by cGvHD had acute GvHD prior, per an Elsevier paper from June 2021.

Government Initiatives

Ongoing support by regulatory bodies toward the production and approval of GvHD medicines is acting as one of the main market drivers of flourishing growth. Research, clinical studies, and the commercialization of promising medicines related to GvHD are receiving significant funding from the government and private sectors. The government is taking initiatives to collaborate with research centers, healthcare professionals, and institutes that deal with this sector. According to the Australian government's Department of Health and Aged Care, new medications are now available for treating esophageal cancer, chronic rhinosinusitis, and GvHD. The new and upgraded medications, which will be covered under the Pharmaceutical Benefits Scheme (PBS), include Opdivo (nivolumab), Jakavi (ruxolitinib), and Nucala (mepolizumab).

Technological Advancements

The treatment techniques for GvHD are expanding at an impressive rate, mostly due to the ongoing progress in medical technology. The ability to diagnose GvHD has greatly improved due to developments in healthcare technologies. Using genome sequencing, biomarker identification, and high-resolution imaging, medical professionals can detect GvHD with high accuracy. Early detection is essential because it enables timely action, which may stop the illness from getting worse. Targeted therapies that are specifically designed to meet the needs of patients with GvHD are now possible due to advancements in medical technology. Promising therapies for GvHD include immunomodulatory medications, biologics, and monoclonal antibodies. These precisely tailored immunological profile-based medicines provide a less harmful and more successful means of controlling the illness.

The development of cellular and gene treatments is one of the biggest developments in the treatment of GvHD. GvHD may be treated with chimeric antigen receptor T-cell (CAR-T) therapy, which targets the immune cells that cause the illness. CRISPR-Cas9 and other gene editing methods show promise for precisely modifying immune cells to prevent or treat GvHD. Innovative medical technology makes these state-of-the-art treatments possible. Treatment has been transformed by the combination of telemedicine and remote monitoring technology, especially when it comes to GvHD. Improved GvHD management and patient outcomes are a result of this accessibility, which also improves patient compliance and overall quality of care. Big data analytics and artificial intelligence (Al) are being utilized to help with GvHD early detection and prevention. Large-scale datasets can be analyzed by machine learning algorithms, which can then spot patterns and risk factors that human clinicians could miss. With the use of this technology, medical professionals can anticipate future GvHD consequences, personalize treatment regimens, and make better decisions.

Research studies from Michigan Medicine, the Children's Hospital of Philadelphia, and Penn Medicine are paving the road for novel gene therapy treatments for blood disorders like sickle cell anemia. A patient still needs chemotherapy and the transplantation of their own corrected cells even after gene therapy corrects the mutation in their cells. However, it is possible to genetically modify blood stem cells in the bone marrow during a single therapy.

Corticosteroids are Dominating the Global Market

Tyrosine kinase inhibitors, corticosteroids, monoclonal antibodies, and other pharmaceuticals make up the product segment of this market. Due to the increasing number of research studies and the rising prevalence of the target disease, the corticosteroid segment retained the biggest share in 2023. Furthermore, the corticosteroid segment is anticipated to grow over the forecast period due to increased research and development efforts focused on corticosteroids and their combinations for the treatment of GvHD in patients undergoing hematopoietic cell transplantation (HCT). Corticosteroids help in managing the immune system and can also limit the activity of donated T-cells in the host's body. It even helps to reduce inflammation caused after the transplant, which regulates the blood pressure well. As of June 2022, an open-label, multicenter, two-arm randomized trial was conducted to evaluate the efficacy of corticosteroids alone or in combination with Ruxolitinib for newly identified high-risk acute gene therapy-related heart failure or dysfunction. It has been observed that roughly 50% of instances of acute graft-versus-host disease (aGvHD) respond to corticosteroid first-line therapy.

North America to Dominate GvHD Market

The North American region is expected to hold a significant market size due to its well-established healthcare infrastructure, ongoing research and development activities, and a growing number of transplant procedures. An increasing number of transplants performed in North America is accelerating market opportunities in the region. Between January 2022 and June 2022, 20,663 transplant procedures were performed in the United States, according to statistics provided by the Organ Procurement and Transplantation Network, which is supervised by the US Department of Health and Human Services and updated in July 2022. Due to the immunological-mediated reactions that take place between the recipients' and donors' adaptive immune systems, the rise in transplant cases may raise demand for therapies for GvHD, which would ultimately spur market demand.

Future Market Scenario (2024 - 2031F)

The growing need to address a variety of symptoms that occur post transplantation processes can fuel the market of GvHD. Increasing number of organ transplantations and the use of new types of inhibitors are also driving market expansion.

The advent of new and improved technologies, well researched drugs, gene editing techniques, and the integration of AI have enabled high accuracy and precision, which, in turn, is anticipated to increase market share in the upcoming years.

Personalised treatment strategies that target genetic alterations and pathways are becoming more and more popular as precision medicine gains traction. AI has also enhanced early detection for any possible indications that further helps the treatment as well as ensure market expansion.

Global regulatory bodies are building frameworks to speed up the development of specialized transplantation departments, which is also driving the expansion of the GvHD market worldwide.

Key Players Landscape and Outlook

There are several significant players in the competitive graft versus host disease market. Currently, the market is dominated by a few dominant players, such as Merck & Co., Inc, Novartis AG, Astellas Pharma Inc., Astra Zeneca PLC, Bayer AG, Boehringer Ingelheim International Gmbh, Abott Inc., Bristol Myers Squibb, Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Elli Lilly and Company, etc. These companies are governing the market share because of their consistent efforts toward R&D, technological advancements, and reliable quality.

Jakavi (ruxolitinib), approved by the European Commission (EC) in May 2022, is intended to treat individuals with acute or chronic GvHD who are 12 years of age or older and do not respond well to corticosteroids or other systemic therapy.

The EQUATOR project, a major Phase III clinical trial of itolizumab in patients with aGvHD, was started by Equillium Inc. in March 2022. When used in conjunction with corticosteroids, itolizumab versus placebo will be evaluated for both safety and efficacy as first-line therapy for aGvHD in this randomized, double-blind study.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Graft Versus Host Disease Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Disease Type
    • 4.2.1. Acute Graft versus Host Disease
    • 4.2.2. Chronic Graft Versus Host Disease
  • 4.3. By Drug Class
    • 4.3.1. Monoclonal Antibodies
    • 4.3.2. Immunosuppressive Drugs
    • 4.3.3. Steroids
    • 4.3.4. TNF Inhibitors
    • 4.3.5. Others
  • 4.4. By Route of Administration
    • 4.4.1. Oral
    • 4.4.2. Intravenous
    • 4.4.3. Others
  • 4.5. By End-user
    • 4.5.1. Hospital Pharmacies
    • 4.5.2. Retail Pharmacies
    • 4.5.3. Online Pharmacies
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia-Pacific
    • 4.6.4. South America
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Graft Versus Host Disease Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Disease Type
      • 5.1.2.1. Acute Graft versus Host Disease
      • 5.1.2.2. Chronic Graft Versus Host Disease
    • 5.1.3. By Drug Class
      • 5.1.3.1. Monoclonal Antibodies
      • 5.1.3.2. Immunosuppressive Drugs
      • 5.1.3.3. Steroids
      • 5.1.3.4. TNF Inhibitors
      • 5.1.3.5. Others
    • 5.1.4. By Route of Administration
      • 5.1.4.1. Oral
      • 5.1.4.2. Parenteral
      • 5.1.4.3. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Research Centers
      • 5.1.5.3. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Disease Type
      • 5.1.6.2.1. Acute Graft versus Host Disease
      • 5.1.6.2.2. Chronic Graft Versus Host Disease
      • 5.1.6.3. By Drug Class
      • 5.1.6.3.1. Monoclonal Antibodies
      • 5.1.6.3.2. Immunosuppressive Drugs
      • 5.1.6.3.3. Steroids
      • 5.1.6.3.4. TNF Inhibitors
      • 5.1.6.3.5. Others
      • 5.1.6.4. By Route of Administration
      • 5.1.6.4.1. Oral
      • 5.1.6.4.2. Parenteral
      • 5.1.6.4.3. Others
      • 5.1.6.5. By End-user
      • 5.1.6.5.1. Hospitals
      • 5.1.6.5.2. Research Centers
      • 5.1.6.5.3. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Disease Type
  • 6.2. By Drug Class
  • 6.3. By Route of Administration
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Merck & Co., Inc
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. Astellas Pharma Inc.
  • 13.4. Astra Zeneca PLC
  • 13.5. Bayer AG
  • 13.6. Boehringer Ingelheim International Gmbh
  • 13.7. Abott Inc.
  • 13.8. Bristol Myers Squibb
  • 13.9. Pfizer Inc.
  • 13.10. F. Hoffmann-La Roche Ltd
  • 13.11. Novartis AG
  • 13.12. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 4. Global Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 5. Global Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Graft versus Host Disease Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 10. North America Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 11. North America Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 12. North America Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13. North America Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Graft versus Host Disease Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 17. United States Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 18. United States Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 19. United States Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 20. United States Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 23. Canada Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 24. Canada Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 25. Canada Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26. Canada Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 29. Mexico Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 30. Mexico Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 31. Mexico Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Mexico Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 35. Europe Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 36. Europe Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 37. Europe Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Europe Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Graft versus Host Disease Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 42. Germany Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 43. Germany Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 44. Germany Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 45. Germany Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. France Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 49. France Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 50. France Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. France Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 54. Italy Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 55. Italy Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 56. Italy Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57. Italy Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 60. United Kingdom Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 61. United Kingdom Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 62. United Kingdom Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. United Kingdom Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 66. Russia Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 67. Russia Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 68. Russia Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69. Russia Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 72. Netherlands Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 73. Netherlands Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 74. Netherlands Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75. Netherlands Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 78. Spain Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 79. Spain Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 80. Spain Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81. Spain Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 84. Turkey Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 85. Turkey Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 86. Turkey Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87. Turkey Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Poland Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 91. Poland Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 92. Poland Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Poland Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 96. South America Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 97. South America Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 98. South America Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. South America Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Graft versus Host Disease Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 103. Brazil Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 104. Brazil Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 105. Brazil Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106. Brazil Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 109. Argentina Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 110. Argentina Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 111. Argentina Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 112. Argentina Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 115. Asia-Pacific Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 116. Asia-Pacific Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 117. Asia-Pacific Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 118. Asia-Pacific Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Graft versus Host Disease Market Share (%), By Country, 2017-2031F
  • Figure 120. India Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 122. India Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 123. India Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 124. India Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. India Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 128. China Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 129. China Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 130. China Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131. China Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 134. Japan Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 135. Japan Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 136. Japan Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137. Japan Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 140. Australia Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 141. Australia Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 142. Australia Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143. Australia Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 146. Vietnam Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 147. Vietnam Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 148. Vietnam Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149. Vietnam Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 152. South Korea Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 153. South Korea Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 154. South Korea Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 155. South Korea Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 158. Indonesia Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 159. Indonesia Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 160. Indonesia Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. Indonesia Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 164. Philippines Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 165. Philippines Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 166. Philippines Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 167. Philippines Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 170. Middle East & Africa Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 171. Middle East & Africa Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 172. Middle East & Africa Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. Middle East & Africa Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Graft versus Host Disease Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 177. Saudi Arabia Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 178. Saudi Arabia Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 179. Saudi Arabia Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180. Saudi Arabia Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. UAE Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 184. UAE Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 185. UAE Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186. UAE Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Graft versus Host Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Graft versus Host Disease Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 189. South Africa Graft versus Host Disease Market Share (%), By Disease Type, 2017-2031F
  • Figure 190. South Africa Graft versus Host Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 191. South Africa Graft versus Host Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192. South Africa Graft versus Host Disease Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023